Beneficial effect of post-procedural abciximab in patients undergoing primary coronary angioplasty and presenting with the no-reflow phenomenon.

Abstract

We sought to investigate the effect of post-procedural abciximab on clinical outcome of patients presenting the no-reflow phenomenon after primary angioplasty. We retrospectively selected 38 patients who developed the no-reflow phenomenon after primary angioplasty: 18 received post-procedural abciximab, 20 age- and sex-matched patients who did not receive abciximab were considered as concurrent controls. At 6 months follow-up, the clinical course was uneventful in the abciximab group while the composite end-point of major adverse cardiac events occurred in 8 patients (40%) in the control group (P=0.009). 'Rescue' administration of abciximab is an effective option for the treatment of the no-reflow phenomenon determining significant prognostic improvements.

• Authors: Andrea Picchi, Valerio Zaca, Marta Focardi, Massimo Fineschi, Giuseppe Sinicropi, Stefano Casini, Alberto Buti, Carlo Pierli, Sergio Mondillo, Mario Marzilli
• Journal: Acute cardiac care (Acute Card Care) Vol. 10 Issue 2 Pg. 100-3 ( 2008) ISSN: 1748-2941 [Print] England
• PMID: 17926148 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Immunoglobulin Fab Fragments
• Platelet Aggregation Inhibitors
• Platelet Glycoprotein GPIIb-IIIa Complex
• Abciximab

Topics

• Abciximab
• Angioplasty, Balloon, Coronary (methods)
• Antibodies, Monoclonal (administration & dosage)
• Coronary Angiography
• Dose-Response Relationship, Drug
• Female
• Follow-Up Studies
• Humans
• Immunoglobulin Fab Fragments (administration & dosage)
• Infusions, Intravenous
• Male
• Middle Aged
• Myocardial Infarction (diagnostic imaging, therapy)
• Platelet Aggregation Inhibitors (administration & dosage)
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
• Retrospective Studies
• Secondary Prevention
• Treatment Outcome